Cretostimogene Cuts NMIBC Recurrence 68% in Phase 3; FDA Rejects Ivonescimab

Cretostimogene slashed the risk of bladder cancer recurrence by 68% in a 367-patient Phase 3 trial, while the same trading day brought an FDA rejection for Summit Therapeutics and a Phase 2 miss for Aclaris' atopic dermatitis antibody.
Monday, November 16, 2026, ran hot and cold for drug developers. The S&P 500 fell 1.92% to 7,416.59 and the Nasdaq Composite dropped 2.49% to 24,509.76, per CNBC's closing report. Against that backdrop, four names moved on clinical and regulatory news: CG Oncology (NASDAQ: CGON), Lexeo Therapeutics (NASDAQ: LXEO), Summit Therapeutics (NASDAQ: SMMT) and Aclaris Therapeutics (NASDAQ: ACRS).
The backdrop matters commercially. Research and Markets projects the global bladder cancer drugs market to grow from USD 6.89 billion in 2026 to USD 11.84 billion by 2032, a 9.41% compound annual growth rate.
What does the PIVOT-006 win change?
CG Oncology reported that its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene met its primary endpoint. The population: intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, tumors 3 cm or less, all following complete tumor resection.
The numbers are strong. Cretostimogene reduced recurrence risk by 68% versus control, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001). The trial enrolled 367 patients across roughly 90 sites in the United States and Canada.
CG Oncology plans to submit a biologics license application on the PIVOT-006 data in the second quarter of 2027. Topline results are scheduled for presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026. Cretostimogene remains an investigational candidate.
Lexeo's gene therapy and a regulatory door opening
Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, its investigational gene therapy for PKP2 arrhythmogenic cardiomyopathy. High-dose participants achieved an 80% mean reduction in non-sustained ventricular tachycardia and a 44% mean reduction in premature ventricular contractions at latest assessment.
Ten participants have been dosed. As of the October 15, 2026 data cutoff, nine had reached at least 12 months of follow-up.
The regulatory signal is just as notable. Lexeo said the FDA is open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020. The update arrived alongside the company's third quarter 2026 financial results.
Why did Summit get a complete response letter?
The FDA issued a complete response letter for Summit's BLA for ivonescimab plus platinum-based chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The agency concluded that substantial evidence of effectiveness is not established absent a statistically significant overall survival improvement.
The application rested on the global Phase III HARMONi trial. There, ivonescimab plus chemotherapy delivered a statistically significant progression-free survival benefit, hazard ratio 0.52, but overall survival showed only a positive trend without reaching statistical significance, per the company's SEC filings. Summit's shares fell 16.5% after the decision, according to the Associated Press.
PFS significance alone didn't carry the application. That's the takeaway for anyone tracking oncology approval standards.
Aclaris misses in atopic dermatitis
Aclaris reported that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), an investigational anti-TSLP monoclonal antibody, missed both primary and secondary endpoints in moderate-to-severe atopic dermatitis. The primary endpoint was percent change from baseline in Eczema Area and Severity Index (EASI) score at week 24.
The biology did what it was supposed to do. Pharmacodynamic results showed robust TSLP target engagement and downregulation of Th1-, Th2- and Th17-related immune-activation biomarkers, and bosakitug was generally well tolerated. Engagement without EASI movement raises questions the topline data can't yet answer.
Aclaris also disclosed that it initiated the Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus.
All four candidates remain investigational, with no approval from the FDA or any other regulator for the uses described. CG Oncology's BLA filing in Q2 2027 and the SUO presentation on December 2, 2026 are the next concrete checkpoints for a bladder cancer field growing toward $11.84 billion by 2032.
Source: prnewswire.com
Sophie Lindqvist
Show full bio
Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.